Intervention
Standard of Care (SoC)
ClinicalTrials.gov intervention label
Advertisement
Clinical trials
7 shownPathToScale: The PERSIST TrialNCT07221747 · 2026-02-16
RECRUITINGAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)NCT07206056 · 2025-10-15
RECRUITINGEvaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Diabetic Foot UlcersNCT07840378 · 2026-09-01
NOT_YET_RECRUITINGAn Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in ChinaNCT05728502 · 2023-04-25
COMPLETEDAn International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANYNCT04575064 · 2020-06-29
WITHDRAWNSafety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic NephropathyNCT03804879 · 2018-12-17
COMPLETEDEMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate CancerNCT01360840 · 2011-04-01
COMPLETEDCommon conditions
Chronic Heart Failure With Reduced Ejection Fraction1COVID-191Diabetic Foot Ulcer (DFU)1Diabetic Nephropathy1Long-acting Injectable Cabotegravir for PrEP1Moderate and Severe COVID-191Oral Pre-exposure Prophylaxis (PrEP)1Progressive Metastatic Castrate Resistant Prostate Cancer1Prostate Cancer Metastatic1SARS-CoV-2 Infection1Ulcer1Wound Closure1Wound Management1
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING2
NOT_YET_RECRUITING1
WITHDRAWN1
Phase mix
PHASE25
PHASE12
NA1
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.